11 December 2024 in Meditsinskiy sovet = Medical Council
This article describes clinical cases of lung damage associated with e-cigarette smoking, EVALI (from E-cigarette and Vaping use-Associated Lung Injury) with a brief review of the literature. With the proliferation and popularization of electronic cigarettes, lung injury associated with their smoking is becoming more common. The term EVALI emerged in 2019 during the largest outbreak in the United States of America (USA), at which time criteria for verifying the diagnosis were developed. This review provides descriptions of a variety of vaping devices and smoking liquids, presents possible mechanisms of lung tissue damage resulting from smoking e-cigarettes, as well as traumatic effects from exploding lithium vape batteries. The most frequent clinical manifestations are respiratory (dyspnea, cough, chest pain, hemoptysis), constitutional (fever, general weakness) and gastroenterologic (nausea, vomiting, diarrhea, abdominal pain) symptoms. The radiologic and histologic pictures of the disease are nonspecific and varied. The diagnosis of “vape disease” includes a wide range of investigations and is a “diagnosis of exclusion”. There are no standardized approaches in the treatment of EVALI, but most patients require oxygen therapy, respiratory support, and the use of systemic glucocorticosteroids. In the current literature there is no information about chronic lung damage against the background of smoking electronic cigarettes. The presented article describes clinical cases of acute lung tissue damage and long-term consequences as a result of vaping. Thus, EVALI is an emerging disease requiring further surveillance and study.
9 October 2025 in PULMONOLOGIYA
Smoking-related lung diseases are diverse, but the most difficult to diagnose remain diseases that involve interstitial changes, in some pathologies combined with emphysema. The aim of the research is to compare the X-ray and morphological features of smoking-related interstitial fibrosis (SRIF). Methods. A histological analysis of surgical samples from 119 patients (smokers and ex-smokers) who underwent lobectomy for lung cancer or other focal lesions in the lungs was performed. Results. Twenty seven patients (18 men, 9 women, 4 ex-smokers) with histological signs of SRIF were identified based on the pathology results; the mean age was 69.1 ± 8.9 years, the smoking index (SI) was 42.06 ± 11.8 pack-years. Results. The prevalence of fibrosis, assessed semi-quantitatively by histological examination, was significantly associated with the SI (r = 0.44; p < 0.05). Fibrosis of the interalveolar septa was observed in areas of emphysema; in addition, signs of chronic bronchiolitis were detected in a third of patients, and constrictive bronchiolitis in 2/3 of patients. The presence of emphysema was correlated with the presence of constrictive bronchiolitis (r = 0.67; p < 0.05). In 11 of 27 patients, fibroblastic foci were found in the walls of the respiratory bronchioles, and their presence also correlated with emphysematous changes (r = 0.40; p < 0.05). CT scans revealed signs of emphysema in 80% patients. In addition; polysegmental areas with ground glass opacities were detected in 12/20 patients, reticular and/or cord-like attenuations were detected in 14 patients, and interlobular interstitial thickening was detected in 8 patients. These signs were assessed as “fibrous” when localized in the emphysema zone. When conducting a correlation analysis, a relationship was found between radiologically detected emphysema and fibrotic changes detected by histological examination (r = 0.50), and the prevalence of CT signs of fibrosis correlated with the presence of fibroblastic foci in the bronchiolar wall (r = 0.51). Conclusion. SRIF is more common in individuals with a smoking history of more than 20 pack-years. CT examination does not always identify the signs of SRIF. In our study, signs of emphysema were detected in 80% patients, and signs possibly associated with fibrosis – in less than half of the cases. Histological results suggest that SRIF is the end stage of the respiratory bronchiolitis of smokers.
7 April 2022 in Meditsinskiy sovet = Medical Council
Introduction. According to modern data, bronchial asthma (BA) is an independent risk factor for the development of cardiac arrhythmias (CA), and the use of long-acting β2-agonists (LABA) in basic therapy may further increase the risks of CA.Aim. To study the structure and risk factors of cardiac arrhythmias in patients with bronchial asthma. Materials and methods. A retrospective study included 181 patients aged 69.4 ± 0.8 years, hospitalized for asthma, with the presence a CA in medical documentation.Results. Among BA patients with CA, supraventricular CA were found in 71.3% (129) patients, ventricular CA in 16.6% (30), combined CA in 12.2% (22). In 52.5% (95) patients, supraventricular extrasystole was detected, in 35.9% (65) – atrial fibrillation, in 28.7% (52) – ventricular extrasystole, in 1.1% (2) – paroxysmal supraventricular tachycardia, in 0.6% (1) – paroxysmal ventricular tachycardia. It was found that supraventricular CA was significantly more frequent among women (χ2 = 5.974, p = 0.05). The severity of BA and the level of control are not related to the type of observed CA (χ2 = 0.755, p = 0.685 and χ2 = 3.003, p = 0.557, respectively).Discussion. The use of a combination of ICS and LABA in basic BA therapy versus the use of ICS alone does not have a significant effect on the frequency and structure of cardiac arrhythmias (χ2 = 1.172, p = 0.556).Conclusion. In hospitalized BA patients, supraventricular cardiac arrhythmias are most often detected, among which supraventricular extrasystole and atrial fibrillation take the main place.